A case of retinal tear associated with use of sorafenib

Inhibition of angiogenesis is a target in the treatment of a variety of malignancies. Sorafenib is an oral inhibitor of multiple tyrosine kinases involved in tumor angiogenesis. A related case of ophthalmologic toxicity has been reported with another vascular endothelial growth factor receptor inhib...

Full description

Bibliographic Details
Main Authors:	Kelly M. Gaertner, Stephen H. Caldwell, Osama eRahma
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2014-07-01
Series:	Frontiers in Oncology
Subjects:	Hepatocellular Carcinoma Sorafenib Retinal tear VEGFR inhibitor Angiogenesis inhibitor
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00196/full

id	doaj-94badede62b246fda52cf2cd324af421
record_format	Article
spelling	doaj-94badede62b246fda52cf2cd324af4212020-11-24T21:23:51ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2014-07-01410.3389/fonc.2014.00196107437A case of retinal tear associated with use of sorafenibKelly M. Gaertner0Stephen H. Caldwell1Osama eRahma2University of Virginia Health SystemUniversity of Virginia Health SystemUniversity of Virginia Health SystemInhibition of angiogenesis is a target in the treatment of a variety of malignancies. Sorafenib is an oral inhibitor of multiple tyrosine kinases involved in tumor angiogenesis. A related case of ophthalmologic toxicity has been reported with another vascular endothelial growth factor receptor inhibitor, sunitinib. We report the first case of retinal tear possibly associated with sorafenib.http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00196/fullHepatocellular CarcinomaSorafenibRetinal tearVEGFR inhibitorAngiogenesis inhibitor
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Kelly M. Gaertner Stephen H. Caldwell Osama eRahma
spellingShingle	Kelly M. Gaertner Stephen H. Caldwell Osama eRahma A case of retinal tear associated with use of sorafenib Frontiers in Oncology Hepatocellular Carcinoma Sorafenib Retinal tear VEGFR inhibitor Angiogenesis inhibitor
author_facet	Kelly M. Gaertner Stephen H. Caldwell Osama eRahma
author_sort	Kelly M. Gaertner
title	A case of retinal tear associated with use of sorafenib
title_short	A case of retinal tear associated with use of sorafenib
title_full	A case of retinal tear associated with use of sorafenib
title_fullStr	A case of retinal tear associated with use of sorafenib
title_full_unstemmed	A case of retinal tear associated with use of sorafenib
title_sort	case of retinal tear associated with use of sorafenib
publisher	Frontiers Media S.A.
series	Frontiers in Oncology
issn	2234-943X
publishDate	2014-07-01
description	Inhibition of angiogenesis is a target in the treatment of a variety of malignancies. Sorafenib is an oral inhibitor of multiple tyrosine kinases involved in tumor angiogenesis. A related case of ophthalmologic toxicity has been reported with another vascular endothelial growth factor receptor inhibitor, sunitinib. We report the first case of retinal tear possibly associated with sorafenib.
topic	Hepatocellular Carcinoma Sorafenib Retinal tear VEGFR inhibitor Angiogenesis inhibitor
url	http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00196/full
work_keys_str_mv	AT kellymgaertner acaseofretinaltearassociatedwithuseofsorafenib AT stephenhcaldwell acaseofretinaltearassociatedwithuseofsorafenib AT osamaerahma acaseofretinaltearassociatedwithuseofsorafenib AT kellymgaertner caseofretinaltearassociatedwithuseofsorafenib AT stephenhcaldwell caseofretinaltearassociatedwithuseofsorafenib AT osamaerahma caseofretinaltearassociatedwithuseofsorafenib
_version_	1725990859924570112

A case of retinal tear associated with use of sorafenib

Similar Items